33.97 USD
0 (0%)
33.99 USD
+0.02 (+0.06%)
Overall VIVO gets a fundamental rating of 6 out of 10. We evaluated VIVO against 185 industry peers in the Health Care Equipment & Supplies industry. VIVO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VIVO has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VIVO had positive earnings in the past year.
VIVO had a positive operating cash flow in the past year.
In the past 5 years VIVO has always been profitable.
VIVO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
VIVO's Return On Assets of 9.17% is amongst the best of the industry. VIVO outperforms 88.89% of its industry peers.
VIVO has a Return On Equity of 11.54%. This is amongst the best in the industry. VIVO outperforms 87.50% of its industry peers.
The Return On Invested Capital of VIVO (14.66%) is better than 94.44% of its industry peers.
VIVO had an Average Return On Invested Capital over the past 3 years of 49.65%. This is significantly above the industry average of 8.82%.
The 3 year average ROIC (49.65%) for VIVO is well above the current ROIC(14.66%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROIC | 14.66% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of VIVO (12.75%) is better than 87.04% of its industry peers.
In the last couple of years the Profit Margin of VIVO has grown nicely.
With an excellent Operating Margin value of 22.70%, VIVO belongs to the best of the industry, outperforming 93.52% of the companies in the same industry.
VIVO's Operating Margin has been stable in the last couple of years.
VIVO has a Gross Margin (56.56%) which is comparable to the rest of the industry.
VIVO's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% |
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
2. Health
2.1 Basic Checks
VIVO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
VIVO has more shares outstanding than it did 1 year ago.
VIVO has a better debt/assets ratio than last year.
2.2 Solvency
VIVO has an Altman-Z score of 11.77. This indicates that VIVO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 11.77, VIVO belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
VIVO has a debt to FCF ratio of 0.34. This is a very positive value and a sign of high solvency as it would only need 0.34 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.34, VIVO belongs to the top of the industry, outperforming 93.52% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that VIVO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.07, VIVO is in line with its industry, outperforming 56.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 11.77 |
ROIC/WACC1.53
WACC9.57%
2.3 Liquidity
A Current Ratio of 3.63 indicates that VIVO has no problem at all paying its short term obligations.
With a Current ratio value of 3.63, VIVO perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
VIVO has a Quick Ratio of 2.46. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.46, VIVO is in line with its industry, outperforming 45.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 |
3. Growth
3.1 Past
The earnings per share for VIVO have decreased strongly by -17.86% in the last year.
The Earnings Per Share has been growing by 15.21% on average over the past years. This is quite good.
Looking at the last year, VIVO shows a small growth in Revenue. The Revenue has grown by 4.76% in the last year.
Measured over the past years, VIVO shows a quite strong growth in Revenue. The Revenue has been growing by 10.65% on average per year.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.62 indicates a rather expensive valuation of VIVO.
83.80% of the companies in the same industry are more expensive than VIVO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of VIVO to the average of the S&P500 Index (26.59), we can say VIVO is valued inline with the index average.
With a Price/Forward Earnings ratio of 40.37, VIVO can be considered very expensive at the moment.
VIVO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. VIVO is cheaper than 75.93% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of VIVO to the average of the S&P500 Index (24.03), we can say VIVO is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
86.57% of the companies in the same industry are more expensive than VIVO, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, VIVO is valued cheaply inside the industry as 94.44% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.27 | ||
| EV/EBITDA | 15.62 |
4.3 Compensation for Growth
VIVO has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.97
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners2.73%
Ins Owner Change0%
Market Cap1.49B
Revenue(TTM)333.02M
Net Income(TTM)42.46M
Analysts43.33
Price Target34.68 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.65%
Min EPS beat(2)-1.96%
Max EPS beat(2)37.25%
EPS beat(4)3
Avg EPS beat(4)27.19%
Min EPS beat(4)-1.96%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-4.52%
Max Revenue beat(2)-0.56%
Revenue beat(4)2
Avg Revenue beat(4)6.92%
Min Revenue beat(4)-4.52%
Max Revenue beat(4)23.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 | ||
| P/S | 4.49 | ||
| P/FCF | 20.27 | ||
| P/OCF | 18.15 | ||
| P/B | 4.06 | ||
| P/tB | 8.42 | ||
| EV/EBITDA | 15.62 |
EPS(TTM)1.38
EY4.06%
EPS(NY)0.84
Fwd EY2.48%
FCF(TTM)1.68
FCFY4.93%
OCF(TTM)1.87
OCFY5.51%
SpS7.57
BVpS8.36
TBVpS4.04
PEG (NY)N/A
PEG (5Y)1.62
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROCE | N/A | ||
| ROIC | 14.66% | ||
| ROICexc | 18.35% | ||
| ROICexgc | 44.57% | ||
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
ROICexc(3y)19.62%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.61%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y13.29%
ROICexc growth 5Y-2.41%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Debt/EBITDA | 0.27 | ||
| Cap/Depr | 52.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 173.69% | ||
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z | 11.77 |
F-Score5
WACC9.57%
ROIC/WACC1.53
Cap/Depr(3y)65.44%
Cap/Depr(5y)57.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)112.8%
Profit Quality(5y)119.92%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.75%
EBIT growth 3Y24.79%
EBIT growth 5Y11.03%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.89%
FCF growth 3Y31.57%
FCF growth 5Y14.86%
OCF growth 1Y23.18%
OCF growth 3Y31.55%
OCF growth 5Y14.77%
MERIDIAN BIOSCIENCE INC / VIVO FAQ
Can you provide the ChartMill fundamental rating for MERIDIAN BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 4 / 10 to VIVO.
What is the valuation status for VIVO stock?
ChartMill assigns a valuation rating of 3 / 10 to MERIDIAN BIOSCIENCE INC (VIVO). This can be considered as Overvalued.
Can you provide the profitability details for MERIDIAN BIOSCIENCE INC?
MERIDIAN BIOSCIENCE INC (VIVO) has a profitability rating of 4 / 10.
What is the valuation of MERIDIAN BIOSCIENCE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MERIDIAN BIOSCIENCE INC (VIVO) is 24.62 and the Price/Book (PB) ratio is 4.06.
What is the earnings growth outlook for MERIDIAN BIOSCIENCE INC?
The Earnings per Share (EPS) of MERIDIAN BIOSCIENCE INC (VIVO) is expected to decline by -39.02% in the next year.